News Releases

Sep 05, 2018
Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

SSIEM presentation included early data from Cohorts 1 (low dose) and 2 (mid dose); enrollment of Cohort 3 (high dose, 5x the mid dose) was recently completed Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks SB-913 has been generally

Aug 08, 2018
Sangamo Therapeutics Reports Second Quarter 2018 Financial Results

Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Today RICHMOND, Calif. , Aug. 8, 2018 /PRNewswire/ --  Sangamo Therapeutics, Inc.

Aug 02, 2018
Sangamo Therapeutics Announces Second Quarter 2018 Conference Call and Webcast

RICHMOND, Calif. , Aug. 2, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Company will release its second quarter 2018 financial results after the market closes on Wednesday, August 8, 2018 . The press release will be followed by a conference call at 5:00

Jul 31, 2018
Sangamo Announces Preliminary Data From Champions Study Evaluating SB-913, An Investigational Genome Editing Treatment For MPS II, To Be Presented September 5th At SSIEM 2018 Symposium

RICHMOND, Calif., July 31, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that preliminary safety and efficacy data from the CHAMPIONS Study, a Phase 1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis Type II (MPS II, also known as Hunter

Displaying 1 - 10 of 37